Long‑acting HIV injections outperform daily pills in young people
Published · Updated
AI-generated summary of the coverage listed below: A Lancet study published in 2024 found that long‑acting injectable cabotegravir, given every eight weeks, provided better protection against HIV than daily oral pre‑exposure prophylaxis (PrEP). The research, conducted by University College London researchers in an African clinical trial, showed higher adherence and lower infection rates among young participants. The findings suggest injections could improve HIV prevention by overcoming daily pill adherence challenges. QUOTE: "HIV injections work better than tablets for young people" — Deccan Herald
Covered by 2 outlets across the spectrum: 0% left, 50% center, 50% right.
Who is covering this story
- Center (1): Deccan Herald
- Right-leaning (1): Times Now
Sources
- HIV injections work better than tablets for young people: Lancet — Deccan Herald (center)
- HIV Prevention Injections May Work Better Than Daily Pills, Lancet Study Finds — Times Now (right-leaning)